Recent incidence trend of surgically resected esophagogastric junction adenocarcinoma and microsatellite instability status in Japanese patients

Yu Imamura, Masayuki Watanabe, Tasuku Toihata, Manabu Takamatsu, Hiroshi Kawachi, Ikumi Haraguchi, Yoko Ogata, Naoya Yoshida, Hiroshi Saeki, Eiji Oki, Kenichi Taguchi, Manabu Yamamoto, Masaru Morita, Shinji Mine, Naoki Hiki, Hideo Baba, Takeshi Sano

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: The incidence trend of esophagogastric junction (EGJ) adenocarcinoma in Japan has not been sufficiently investigated. Little is known about the microsatellite instability (MSI) status of this tumor. Summary: Previously published studies analyzing the trend of EGJ adenocarcinoma in Japan were reviewed. And a trend of surgically resected cases (Siewert type I-III) utilizing a retrospective multicenter cohort of 379 patients from 4 academic institutions in Japan investigated. Although an increasing trend in the last 2 reports was considered controversial, our cohort demonstrated a growing number of EGJ adenocarcinoma cases between 2006 and 2013. This trend was evident, especially in Siewert type I cases. In the previous 16 studies that performed MSI testing, MSI-high tumors ranged 0-8.3%, though there were no fixed microsatellite markers on EGJ adenocarcinoma. In a recent comprehensive genetic analysis by The Cancer Genome Atlas, MSI testing using the following 7 markers, BAT25, BAT26, BAT40, D2S123, D5S346, D17S250 and TGFR-II showed a favorable correlation with hypermutated tumors. We performed MSI testing using 6 of those markers, except TGFR-II, on 206 cases from one institution, and detected 15 cases (7.3%) with MSI-high. The prevalence of MSI-high was 0% in Siewert type I, 7.6% in type II, and 16.7% in type III. Key message: The number of surgically resected EGJ adenocarcinoma cases gradually increased, and MSI-high was infrequent in Siewert type I-II tumors in our Japanese cohort. Considering MSI-high as a predictive biomarker for emerging immune checkpoint inhibitors, MSI status is becoming more beneficial in EGJ adenocarcinoma.

Original languageEnglish
Pages (from-to)6-13
Number of pages8
JournalDigestion
Volume99
Issue number1
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Esophagogastric Junction
Microsatellite Instability
Adenocarcinoma
Incidence
Japan
Neoplasms
Atlases
Microsatellite Repeats
Biomarkers
Genome

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Recent incidence trend of surgically resected esophagogastric junction adenocarcinoma and microsatellite instability status in Japanese patients. / Imamura, Yu; Watanabe, Masayuki; Toihata, Tasuku; Takamatsu, Manabu; Kawachi, Hiroshi; Haraguchi, Ikumi; Ogata, Yoko; Yoshida, Naoya; Saeki, Hiroshi; Oki, Eiji; Taguchi, Kenichi; Yamamoto, Manabu; Morita, Masaru; Mine, Shinji; Hiki, Naoki; Baba, Hideo; Sano, Takeshi.

In: Digestion, Vol. 99, No. 1, 01.12.2018, p. 6-13.

Research output: Contribution to journalArticle

Imamura, Y, Watanabe, M, Toihata, T, Takamatsu, M, Kawachi, H, Haraguchi, I, Ogata, Y, Yoshida, N, Saeki, H, Oki, E, Taguchi, K, Yamamoto, M, Morita, M, Mine, S, Hiki, N, Baba, H & Sano, T 2018, 'Recent incidence trend of surgically resected esophagogastric junction adenocarcinoma and microsatellite instability status in Japanese patients', Digestion, vol. 99, no. 1, pp. 6-13. https://doi.org/10.1159/000494406
Imamura, Yu ; Watanabe, Masayuki ; Toihata, Tasuku ; Takamatsu, Manabu ; Kawachi, Hiroshi ; Haraguchi, Ikumi ; Ogata, Yoko ; Yoshida, Naoya ; Saeki, Hiroshi ; Oki, Eiji ; Taguchi, Kenichi ; Yamamoto, Manabu ; Morita, Masaru ; Mine, Shinji ; Hiki, Naoki ; Baba, Hideo ; Sano, Takeshi. / Recent incidence trend of surgically resected esophagogastric junction adenocarcinoma and microsatellite instability status in Japanese patients. In: Digestion. 2018 ; Vol. 99, No. 1. pp. 6-13.
@article{1825cff8915f4a7e91c55cdcbe55eeff,
title = "Recent incidence trend of surgically resected esophagogastric junction adenocarcinoma and microsatellite instability status in Japanese patients",
abstract = "Background: The incidence trend of esophagogastric junction (EGJ) adenocarcinoma in Japan has not been sufficiently investigated. Little is known about the microsatellite instability (MSI) status of this tumor. Summary: Previously published studies analyzing the trend of EGJ adenocarcinoma in Japan were reviewed. And a trend of surgically resected cases (Siewert type I-III) utilizing a retrospective multicenter cohort of 379 patients from 4 academic institutions in Japan investigated. Although an increasing trend in the last 2 reports was considered controversial, our cohort demonstrated a growing number of EGJ adenocarcinoma cases between 2006 and 2013. This trend was evident, especially in Siewert type I cases. In the previous 16 studies that performed MSI testing, MSI-high tumors ranged 0-8.3{\%}, though there were no fixed microsatellite markers on EGJ adenocarcinoma. In a recent comprehensive genetic analysis by The Cancer Genome Atlas, MSI testing using the following 7 markers, BAT25, BAT26, BAT40, D2S123, D5S346, D17S250 and TGFR-II showed a favorable correlation with hypermutated tumors. We performed MSI testing using 6 of those markers, except TGFR-II, on 206 cases from one institution, and detected 15 cases (7.3{\%}) with MSI-high. The prevalence of MSI-high was 0{\%} in Siewert type I, 7.6{\%} in type II, and 16.7{\%} in type III. Key message: The number of surgically resected EGJ adenocarcinoma cases gradually increased, and MSI-high was infrequent in Siewert type I-II tumors in our Japanese cohort. Considering MSI-high as a predictive biomarker for emerging immune checkpoint inhibitors, MSI status is becoming more beneficial in EGJ adenocarcinoma.",
author = "Yu Imamura and Masayuki Watanabe and Tasuku Toihata and Manabu Takamatsu and Hiroshi Kawachi and Ikumi Haraguchi and Yoko Ogata and Naoya Yoshida and Hiroshi Saeki and Eiji Oki and Kenichi Taguchi and Manabu Yamamoto and Masaru Morita and Shinji Mine and Naoki Hiki and Hideo Baba and Takeshi Sano",
year = "2018",
month = "12",
day = "1",
doi = "10.1159/000494406",
language = "English",
volume = "99",
pages = "6--13",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Recent incidence trend of surgically resected esophagogastric junction adenocarcinoma and microsatellite instability status in Japanese patients

AU - Imamura, Yu

AU - Watanabe, Masayuki

AU - Toihata, Tasuku

AU - Takamatsu, Manabu

AU - Kawachi, Hiroshi

AU - Haraguchi, Ikumi

AU - Ogata, Yoko

AU - Yoshida, Naoya

AU - Saeki, Hiroshi

AU - Oki, Eiji

AU - Taguchi, Kenichi

AU - Yamamoto, Manabu

AU - Morita, Masaru

AU - Mine, Shinji

AU - Hiki, Naoki

AU - Baba, Hideo

AU - Sano, Takeshi

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: The incidence trend of esophagogastric junction (EGJ) adenocarcinoma in Japan has not been sufficiently investigated. Little is known about the microsatellite instability (MSI) status of this tumor. Summary: Previously published studies analyzing the trend of EGJ adenocarcinoma in Japan were reviewed. And a trend of surgically resected cases (Siewert type I-III) utilizing a retrospective multicenter cohort of 379 patients from 4 academic institutions in Japan investigated. Although an increasing trend in the last 2 reports was considered controversial, our cohort demonstrated a growing number of EGJ adenocarcinoma cases between 2006 and 2013. This trend was evident, especially in Siewert type I cases. In the previous 16 studies that performed MSI testing, MSI-high tumors ranged 0-8.3%, though there were no fixed microsatellite markers on EGJ adenocarcinoma. In a recent comprehensive genetic analysis by The Cancer Genome Atlas, MSI testing using the following 7 markers, BAT25, BAT26, BAT40, D2S123, D5S346, D17S250 and TGFR-II showed a favorable correlation with hypermutated tumors. We performed MSI testing using 6 of those markers, except TGFR-II, on 206 cases from one institution, and detected 15 cases (7.3%) with MSI-high. The prevalence of MSI-high was 0% in Siewert type I, 7.6% in type II, and 16.7% in type III. Key message: The number of surgically resected EGJ adenocarcinoma cases gradually increased, and MSI-high was infrequent in Siewert type I-II tumors in our Japanese cohort. Considering MSI-high as a predictive biomarker for emerging immune checkpoint inhibitors, MSI status is becoming more beneficial in EGJ adenocarcinoma.

AB - Background: The incidence trend of esophagogastric junction (EGJ) adenocarcinoma in Japan has not been sufficiently investigated. Little is known about the microsatellite instability (MSI) status of this tumor. Summary: Previously published studies analyzing the trend of EGJ adenocarcinoma in Japan were reviewed. And a trend of surgically resected cases (Siewert type I-III) utilizing a retrospective multicenter cohort of 379 patients from 4 academic institutions in Japan investigated. Although an increasing trend in the last 2 reports was considered controversial, our cohort demonstrated a growing number of EGJ adenocarcinoma cases between 2006 and 2013. This trend was evident, especially in Siewert type I cases. In the previous 16 studies that performed MSI testing, MSI-high tumors ranged 0-8.3%, though there were no fixed microsatellite markers on EGJ adenocarcinoma. In a recent comprehensive genetic analysis by The Cancer Genome Atlas, MSI testing using the following 7 markers, BAT25, BAT26, BAT40, D2S123, D5S346, D17S250 and TGFR-II showed a favorable correlation with hypermutated tumors. We performed MSI testing using 6 of those markers, except TGFR-II, on 206 cases from one institution, and detected 15 cases (7.3%) with MSI-high. The prevalence of MSI-high was 0% in Siewert type I, 7.6% in type II, and 16.7% in type III. Key message: The number of surgically resected EGJ adenocarcinoma cases gradually increased, and MSI-high was infrequent in Siewert type I-II tumors in our Japanese cohort. Considering MSI-high as a predictive biomarker for emerging immune checkpoint inhibitors, MSI status is becoming more beneficial in EGJ adenocarcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85058809633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058809633&partnerID=8YFLogxK

U2 - 10.1159/000494406

DO - 10.1159/000494406

M3 - Article

C2 - 30554205

AN - SCOPUS:85058809633

VL - 99

SP - 6

EP - 13

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 1

ER -